Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.
Gerecitano
John
J
Department of Medicine, Memorial Sloan Kettering Cancer Center, Columbia University, New York, NY 10021, USA. gerecitj@mskcc.org
Portlock
Carol
C
Moskowitz
Craig
C
Hamlin
Paul
P
Straus
David
D
Zelenetz
Andrew D
AD
Zhang
Zhigang
Z
Dumitrescu
Otilia
O
Sarasohn
Debra
D
Lin
Dorothy
D
Pappanicholaou
Jennifer
J
Cortelli
Barbara M
BM
Neylon
Ellen
E
Hamelers
Rachel
R
Wright
John
J
O'Connor
Owen A
OA
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib